As an antidiabetic drug of DPP-4 inhibitor, the marketing of Tregliptin in China is the focus of attention of diabetes patients. According to the existing information, the drug has been approved for marketing in China and patients can obtain it with a prescription from formal medical institutions.

1. Domestic listing status

(1) Approval status: Quegliptin has been approved by the China National Medical Products Administration and has obtained the qualification for domestic marketing.

(2) Listing time: The specific approval time can be found on the NMPA official website or consulted with drug manufacturers.

2 Medication precautions

(1) Purchase channel: It is recommended to purchase through regular hospitals or pharmacies to ensure the quality of the drugs.

(2) Prescription requirement: This medication is a prescription drug and must be purchased and used with a physician's prescription.

3. Verification of Drug Information

(1) Batch number inquiry: When purchasing, you can request to view the drug approval number and verify it through the website of the National Medical Products Administration.

(2) Production date: Pay attention to checking the production date and expiration date on the drug packaging.

4 references for similar drugs

(1) Other DPP-4 inhibitors, such as sitagliptin and vildagliptin, have been launched in China.

(2) Combination therapy: It can be used in combination with hypoglycemic drugs such as metformin, but the dosage needs to be adjusted according to medical advice.